Recurrent Ovarian Carcinoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Recruiting
  • Advanced Malignant Solid Neoplasm
  • +49 more
  • Birmingham, Alabama
  • +1423 more
2022-04-06
Apr 6, 2022
O
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Active, not recruiting
  • BRCA1 Gene Mutation
  • +9 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-04-05
Apr 5, 2022
S
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Active, not recruiting
  • Advanced Solid Tumors
  • +4 more
  • Phoenix, Arizona
  • +15 more
2022-04-04
Apr 4, 2022
N
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
Suspended
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +25 more
  • Pegylated Liposomal Doxorubicin Hydrochloride
  • Peposertib
  • Aurora, Colorado
  • +7 more
2022-04-05
Apr 5, 2022
M
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study
Recruiting
  • Malignant Abdominal Neoplasm
  • +26 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2022-04-05
Apr 5, 2022
N
Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Recruiting
  • Quality of Life
  • +2 more
  • Trabectidin (Yondelis)
  • Aachen, Germany
  • +32 more
2022-04-05
Apr 5, 2022
N
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
Recruiting
  • Recurrent Endometrial Endometrioid Adenocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +569 more
2022-04-05
Apr 5, 2022
N
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Active, not recruiting
  • Fallopian Tube High Grade Serous Adenocarcinoma
  • +18 more
  • Anchorage, Alaska
  • +928 more
2022-04-05
Apr 5, 2022
N
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Active, not recruiting
  • Metastatic Fallopian Tube Carcinoma
  • +11 more
  • Phoenix, Arizona
  • +13 more
2022-04-05
Apr 5, 2022
N
Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Active, not recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +7 more
  • Cediranib Maleate
  • +2 more
  • Phoenix, Arizona
  • +19 more
2022-04-05
Apr 5, 2022
N
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Recruiting
  • Advanced Differentiated Thyroid Gland Carcinoma
  • +102 more
  • Cabozantinib S-malate
  • Nivolumab
  • Chicago, Illinois
  • +2 more
2022-04-05
Apr 5, 2022
R
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
2022-04-04
Apr 4, 2022
L
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
Recruiting
  • Recurrent Ovarian Carcinoma
  • +7 more
  • Niraparib plus anlotinib
  • Beijing, Beijing, China
    Lei Li
2022-03-27
Mar 27, 2022
W
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Recruiting
  • Solid Tumor, Adult
  • +27 more
  • Blood draws
  • +2 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
2022-04-04
Apr 4, 2022
L
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
Recruiting
  • Ovarian Carcinoma
  • +6 more
  • Albumin-bound paclitaxel and bevacizumab
  • Beijing, Beijing, China
    Lei Li
2022-03-26
Mar 26, 2022
N
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Tucson, Arizona
  • +16 more
2022-04-01
Apr 1, 2022
V
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers - 2022
Terminated
  • Fallopian Tube Cancer
  • +12 more
  • Kansas City, Kansas
  • +1 more
2022-03-23
Mar 23, 2022
N
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Active, not recruiting
Has Results
  • Clear Cell Adenocarcinoma
  • +24 more
  • Bevacizumab
  • +6 more
  • Anchorage, Alaska
  • +717 more
2022-03-01
Mar 1, 2022
N
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
2022-03-10
Mar 10, 2022
M
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
2022-03-09
Mar 9, 2022
U
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-10
Mar 10, 2022
M
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
Active, not recruiting
Has Results
  • Ovarian Serous Tumor
  • Recurrent Ovarian Carcinoma
  • Rochester, Minnesota
    Mayo Clinic
2022-03-22
Mar 22, 2022
N
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Active, not recruiting
  • Ovarian Serous Tumor
  • +3 more
  • Phoenix, Arizona
  • +16 more
2022-03-23
Mar 23, 2022
M
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
Recruiting
  • Malignant Peritoneal Neoplasm
  • +33 more
  • Ipilimumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-08
Mar 8, 2022
R
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +10 more
  • Bevacizumab
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2022-03-14
Mar 14, 2022